Hossein Madineh1, Omolbanin Rahimi2, Mohamadreza Abedin Zadeh2, Majid Kabiri2. 1. Assistant Professor, Department of Anesthesiology, Shahrekord University of Medical Sciences, Kashani Hospital, Shahrekord, Iran. 2. Assistant Professor, Department of Anesthesiology, Kashani Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Abstract
INTRODUCTION:Ventilator Associated Pneumonia (VAP) is the second most common infection with high mortality (24-50%). Ondansetron is a reliable and safe drug and it is currently used in the prevention of nausea and vomiting and has no side effects. AIM: The aim of the present study was to examine the effect of ondansetron on prevention of VAP in Intensive Care Unit (ICU) patients. MATERIALS AND METHODS: The present study was a randomized clinical trial study (IRCT201406156480N6), carried out at Kashani Hospital, Iran, in 2013 on 80 patients aged from 15-65 years. The patients were randomly allocated to two groups: Case group (n=40) and Control group (n=40). The patients in first group were injected with 4 mg ondansetron, twice daily for five days. The patients of other group were injected with distilled water as placebo. The presence of VAP was assessed in the two groups. The collected data were analysed by SPSS software through Fisher-exact test. RESULTS: Eleven (13.8%) patients were diagnosed with VAP. Among them, 9 (81.8%) patients were male and 2 (18.2%) patients were female. The incidence of VAP in Case group was 5 (12.5%) patients and in Control group was 6 (15%) patients (p>0.05). Results showed that VAP in Case group was less prevalent than that in the Control group, but this difference was not significant. CONCLUSION: The study did not find an association between ondansetron administration and reduction in VAP incidence; vomiting alone may not be leading to VAP, instead silent micro aspirations may be the cause of it. None of the factor such as age, sex, weight, smoking, drug addiction was found significantly related to VAP. Only variable found related was comorbidity.
RCT Entities:
INTRODUCTION: Ventilator Associated Pneumonia (VAP) is the second most common infection with high mortality (24-50%). Ondansetron is a reliable and safe drug and it is currently used in the prevention of nausea and vomiting and has no side effects. AIM: The aim of the present study was to examine the effect of ondansetron on prevention of VAP in Intensive Care Unit (ICU) patients. MATERIALS AND METHODS: The present study was a randomized clinical trial study (IRCT201406156480N6), carried out at Kashani Hospital, Iran, in 2013 on 80 patients aged from 15-65 years. The patients were randomly allocated to two groups: Case group (n=40) and Control group (n=40). The patients in first group were injected with 4 mg ondansetron, twice daily for five days. The patients of other group were injected with distilled water as placebo. The presence of VAP was assessed in the two groups. The collected data were analysed by SPSS software through Fisher-exact test. RESULTS: Eleven (13.8%) patients were diagnosed with VAP. Among them, 9 (81.8%) patients were male and 2 (18.2%) patients were female. The incidence of VAP in Case group was 5 (12.5%) patients and in Control group was 6 (15%) patients (p>0.05). Results showed that VAP in Case group was less prevalent than that in the Control group, but this difference was not significant. CONCLUSION: The study did not find an association between ondansetron administration and reduction in VAP incidence; vomiting alone may not be leading to VAP, instead silent micro aspirations may be the cause of it. None of the factor such as age, sex, weight, smoking, drug addiction was found significantly related to VAP. Only variable found related was comorbidity.
Entities:
Keywords:
Inflammation of the lung; Nosocomial infections; Pulmonary diseases; Respiratory tract diseases
Authors: Claar D van der Maarel-Wierink; Jackie N O Vanobbergen; Ewald M Bronkhorst; Jos M G A Schols; Cees de Baat Journal: Gerodontology Date: 2012-03-06 Impact factor: 2.980
Authors: João Manoel da Silva; Ederlon Rezende; Thaís Guimarães; Edvaldo V dos Campos; Luiz André Magno; Lívia Consorti; Renata Andréa Pietro Pereira; Maria de Lourdes Nascimento; João Silva de Mendonça Journal: Braz J Infect Dis Date: 2007-10 Impact factor: 1.949
Authors: Emilio Bouza; Ana Pérez; Patricia Muñoz; M Jesús Pérez; Cristina Rincón; Carlos Sánchez; Pablo Martín-Rabadán; Mariano Riesgo Journal: Crit Care Med Date: 2003-07 Impact factor: 7.598